ROIV
Roivant Sciences Ltd. Health Care Pharmaceutical Preparations Russell 3000
$36.91Close
$26.6BMarket cap
$19.58 – $41.8152-week range
Nov 9, 2026Next report · before the open
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 92 · stronger than 92% of stocks over 12 months
- Tight base near its pivot pullbacks 22% → 7%; 4.1% below its $38.49 pivot
Cautions
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
12%
1wk
up 1.2%
price change
1mo
up 0.9%
price change
12-month return
up 89%
market up 11% ·
its own up 86%
F-score
—
— Not assessed
Altman Z
38.93
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
5.9×
price / book
Earnings yield
down 2.0%
EBIT / enterprise value
Cheaper than
21%
of the market · expensive
Revenue growth
down 72%
year on year
EPS growth
—
latest quarter
Sales growth
down 34%
latest quarter · +33 pts
ROE
down 7%
return on equity
Free cash margin
down 9184%
-$758.6M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
3.6%
$1.31 a day · 2×ATR $34.29
RS
92 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.83
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Contractions
2
22% → 7%
Pivot
$38.49
4.1% below
Volume dry-up
1.0×
10 vs 50 sessions
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 3.5% over the year, from 696m to 720m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 71.6% over the year, from $29.1M to $8.3M.
Last reported
Aug 6, 2026
Results reaction
Aug 6, 2026+5% vs market2 sessions after results
Financials
- Net -3629%
- Free cash -9184%
- Cash
- Long-term debt
| FY2021Mar 31, 2021 | FY2022Mar 31, 2022 | FY2023Mar 31, 2023 | FY2024Mar 31, 2024 | FY2025Mar 31, 2025 | FY2026Mar 31, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Operating income | -$1.1B | -$1.4B | -$906.8M | $4.5B | -$1.0B | -$515.1M |
| Net income | -$809.2M | -$845.3M | -$1.0B | $4.3B | -$172.0M | -$299.8M |
| Net margin | -3401% | -1529% | -3200% | 13294% | -592% | -3629% |
| Earnings per share | — | -$1.26 | -$1.42 | $5.23 | -$0.24 | -$0.43 |
| Free cash flow | -$557.9M | -$695.2M | -$856.1M | -$766.6M | -$844.0M | -$758.6M |
| Free cash margin | -2345% | -1257% | -2715% | -2344% | -2905% | -9184% |
| Cash | $2.1B | $2.1B | $1.7B | $6.5B | $2.7B | $1.4B |
| Long-term debt | $170.3M | $210.0M | $375.5M | $430.6M | — | — |
| Shareholders' equity | $1.8B | $1.7B | $1.2B | $6.0B | $4.7B | $4.5B |
| Shares outstanding | 651.58m | 694.98m | 760.14m | 806.68m | 695.94m | 720.35m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 6, 2026 | Quarterly ↗ | Jun 30, 2026 | 37d |
| May 20, 2026 | Annual ↗ | Mar 31, 2026 | 50d |
| Feb 6, 2026 | Quarterly ↗ | Dec 31, 2025 | 37d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 29, 2025 | Annual ↗ | Mar 31, 2025 | 59d |
| Feb 10, 2025 | Quarterly ↗ | Dec 31, 2024 | 41d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 9, 2024 | Quarterly ↗ | Jun 30, 2024 | 40d |
| May 30, 2024 | Annual ↗ | Mar 31, 2024 | 60d |
| Feb 13, 2024 | Quarterly ↗ | Dec 31, 2023 | 44d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 21, 2026 | Regulation FD ↗ |
| Sep 18, 2026 | Shareholder vote ↗ |
| Sep 8, 2026 | Regulation FD ↗ |
| Aug 28, 2026 | Other events ↗ |
| Aug 27, 2026 | Regulation FD ↗ |
| Aug 6, 2026 | Results ↗ |
| May 20, 2026 | Results ↗ |
| Apr 2, 2026 | Results · Regulation FD ↗ |
| Mar 3, 2026 | Material agreement · Regulation FD · Other events ↗ |
| Mar 3, 2026 | Regulation FD ↗ |
| Feb 6, 2026 | Results ↗ |
| Dec 11, 2025 | Regulation FD ↗ |